文献速递系统性红斑狼疮

贝利尤单抗处方与结局的10年单中心队列分析:早期使用是否有优势

Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?
PubMed 文献 · RMD Open · 2024-04-12

基于比萨狼疮队列中102例接受贝利尤单抗治疗的系统性红斑狼疮患者,回顾性分析显示6个月和12个月分别有47%和38%及75%和66%的患者达到LLDAS5和缓解;未接受过免疫抑制剂的患者与接受过者疗效无显著差异,但前者6个月和12个月泼尼松日剂量显著更低,且近年未接受过免疫抑制剂者更常见。

要点

  • 贝利尤单抗治疗6个月和12个月时分别有47%和75%的患者达到LLDAS5,38%和66%达到缓解。
  • 未接受过免疫抑制剂者与接受过者在基线特征及LLDAS5和缓解达成上无显著差异。
  • 未接受过免疫抑制剂者6个月和12个月时泼尼松日剂量显著低于接受过者。

核心结论

  • 贝利尤单抗能有效控制疾病活动,近年来越来越多地在其他免疫抑制剂之前作为早期治疗选择。
  • 早期引入贝利尤单抗至少与升阶梯方案同样有效,并有助于减少糖皮质激素剂量。

研究设计与样本

  • 回顾性分析前瞻性收集的数据,来自比萨系统性红斑狼疮队列的422例患者中,102例接受贝利尤单抗治疗并纳入分析。

主要发现

  • 102例中22例(21.6%)为未接受过免疫抑制剂者。
  • 6个月时47%达到LLDAS5、38%达到缓解;12个月时75%达到LLDAS5、66%达到缓解。
  • 未接受过免疫抑制剂者与至少接受过一种传统免疫抑制剂后使用贝利尤单抗者相比,基线特征及LLDAS5和缓解达成无显著差异。
  • 基线时两组平均泼尼松日剂量无显著差异,但未接受过免疫抑制剂者6个月和12个月时泼尼松日剂量显著更低。
  • 未接受过免疫抑制剂者在最近年份更常见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective is to evaluate perscriptions of belimumab (BEL), how these have changed over the years and their impact on clinical outcomes in patients with systemic lupus erythematosus (SLE). METHODS: This is a retrospective analysis of prospectively collected data. We retrieved demographic and clinical data and concomitant therapies at BEL starting (baseline). Disease activity was assessed at baseline and after 6 and 12 months and organ damage at baseline and at the last visit. RESULTS: From 422 patients followed in the Pisa SLE cohort, 102 patients received BEL and were included and 22 (21.6%) were immunosuppressant (IS)-naïve. Lupus Low Disease Activity State (LLDAS) with a glucocorticoid (GC) dosage ≤5 mg/day (LLDAS5) and remission were achieved by 47% and 38% of patients at 6 months, and by 75% and 66% at 12 months. Comparing IS-naïve patients with those who received BEL after at least one conventional IS, we did not find significant differences in baseline characteristics and in the achievement of LLDAS5 and remission. Despite at baseline we did not observe significant differences in mean GC daily dosage, IS-naïve patients were taking a significantly lower GC daily dose at 6 and 12 months. Interestingly, IS-naïve patients were more common in the most recent years. CONCLUSIONS: Our data confirm that BEL is effective in controlling disease activity, and in recent years BEL has been considered as an earlier treatment option before other IS. Early introduction of BEL can be at least as effective as a step-up approach and can help to reduce the GC dosage.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Tani C, Zucchi D, Cardelli C, et al. Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use? RMD Open. 2024. PMID: 38609320. doi:10.1136/rmdopen-2023-003981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。